Search results for "dose modification"

showing 3 items of 3 documents

An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C

2010

Purpose Treatment of patients with chronic hepatitis C with alpha-interferon and ribavirin usually produces adverse events within the first 3 months. We aimed to assess safety and predictors of discontinuation or dose modification of these drugs. Methods Observational study of 312 patients with predominantly genotype 1 chronic hepatitis C treated openly along 5 years in a clinical practice setting. Results Eighty-four percent of patients experienced at least one adverse event (853 events in total, 3.3 per patient on average). Incidence rate was higher during the first 90 days and decreased thereafter (<5%). Discontinuation rates at 30 and 90 days and at end of treatment were 2, 4 and 8%, re…

AdultMalemedicine.medical_specialtyGenotypeEpidemiologyadverse eventHepacivirusAntiviral AgentsSettore MED/01 - Statistica MedicaMedication Adherencechemistry.chemical_compoundChronic hepatitisInternal medicineRibavirinHumansMedicinePharmacology (medical)Dual therapyAdverse effectDose ModificationSettore MED/12 - GastroenterologiaDose-Response Relationship Drugbusiness.industryIncidenceRibavirinAge FactorsAntiviral therapyInterferon-alphainterferonpredictionHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurgeryDiscontinuationchemistryDrug Therapy CombinationFemalehepatitis CbusinessPharmacoepidemiology and Drug Safety
researchProduct

Refining sorafenib therapy: lessons from clinical practice

2015

ABSTRACT  Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symp…

Cancer ResearchSettore SECS-P/06 - Economia ApplicataAntineoplastic AgentAge FactorChild–Pugh Bpostprogression treatmentresponse assessmentdose modificationClinical Trials as TopicLiver Neoplasmsadverse event managementAge FactorsChild-Pugh Bpostprogression treatmenthepatocellular carcinomaGeneral MedicinePrognosisadverse event management; child–Pugh B; dose modification; elderly hepatocellular carcinoma; mRECIST; postprogression treatment; eal-world data; response assessment; sorafenibelderly hepatocellular carcinomaCombined Modality Therapychild–Pugh BClinical PracticeTreatment OutcomeOncologyLiver Neoplasmeal-world dataHepatocellular carcinomaadverse event managementRetreatmentDisease Progressiondose modificationHumanmedicine.drugPhenylurea CompoundNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularDisease ResponsePrognosielderly hepatocellular carcinomaProtein Kinase InhibitorAntineoplastic AgentsmRECISTelderlymRECISTAdverse event management Child–Pugh B dose modification elderly hepatocellular carcinoma mRECIST postprogression treatment real-world data response assessment sorafenibmedicineChild–Pugh BHumansCombined Modality TherapyIntensive care medicineAdverse effectProtein Kinase InhibitorsDose Modificationreal-world databusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationSurgeryreal-world dataresponse assessmentsorafenibbusinessFuture Oncology
researchProduct

Heart rate control with oral ivabradine in computed tomography coronary angiography: a randomized comparison of 7.5 mg vs 5 mg regimen.

2013

Background: Heart rate (HR) reduction is essential to achieve optimal image quality and diagnostic accuracy with computed tomography coronary angiography (CTCA). Administration of oral ivabradine seems to be more effective than beta-blockade in reducing HR in patients referred for CTCA. Methods: Two-hundred-fifty-nine consecutive patients referred for CTCA were prospectively enrolled. Patients not receiving beta-blocker at baseline (group 1) and those with beta-blocker therapy (group 2) were enrolled in the study. Each group was randomized into 3 parallel arms with 1:1:1 allocation. Patients who did not receive beta-blocker at baseline: underwent CTCA without beta blocker (n=49), and receiv…

Coronary angiographyMalemedicine.medical_specialtymedicine.drug_classAdministration OralComputed tomographyCoronary Artery DiseaseCoronary AngiographyComputed tomography coronary angiographyCohort StudiesHeart RateInternal medicineHeart ratemedicineHumansIvabradineProspective StudiesHeart rate reductionBeta blockerDose ModificationAgedRetrospective Studiesmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryBenzazepinesMiddle AgedCoronary heart diseaseRegimenBlood pressureAnesthesiaCardiologyFemaleCardiology and Cardiovascular MedicinebusinessTomography X-Ray ComputedIvabradinemedicine.drug
researchProduct